250 related articles for article (PubMed ID: 34150798)
1. Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2- Advanced or Metastatic Breast Cancer: A US Payer Perspective.
Wang Y; Rui M; Guan X; Cao Y; Chen P
Front Med (Lausanne); 2021; 8():658747. PubMed ID: 34150798
[No Abstract] [Full Text] [Related]
2. Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy.
Colombo GL; Valentino MC; Fabi A; Dieci MV; Caruggi M; Bruno GM; Lombardi G; Di Matteo S
Ther Clin Risk Manag; 2023; 19():301-312. PubMed ID: 37013197
[TBL] [Abstract][Full Text] [Related]
3. Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2- Advanced Breast Cancer.
Fasching PA; Delea TE; Lu YS; De Boer R; Hurvitz SA; Moynahan A; Chandiwana D; Lanoue B; Hu H; Thuerigen A; O'Shaughnessy J
Cancer Manag Res; 2021; 13():8179-8189. PubMed ID: 34754238
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
[TBL] [Abstract][Full Text] [Related]
5. Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis.
Berrios K; Burum A; Jeong E; Zhong L
J Manag Care Spec Pharm; 2022 Nov; 28(11):1282-1291. PubMed ID: 36282933
[No Abstract] [Full Text] [Related]
6. Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer.
Rugo HS; Haltner A; Zhan L; Tran A; Bananis E; Hooper B; Mitra D; Cameron C
J Comp Eff Res; 2021 Apr; 10(6):457-467. PubMed ID: 33626934
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
Zhang B; Long EF
Breast Cancer Res Treat; 2019 Jun; 175(3):775-779. PubMed ID: 30847728
[TBL] [Abstract][Full Text] [Related]
8. Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2- Metastatic Breast Cancer in Postmenopausal Women in the USA.
Masurkar PP; Damgacioglu H; Deshmukh AA; Trivedi MV
Pharmacoeconomics; 2023 Jun; 41(6):709-718. PubMed ID: 36920662
[TBL] [Abstract][Full Text] [Related]
9. Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective.
Stellato D; Thabane ME; Park J; Chandiwana D; Delea TE
Pharmacoeconomics; 2021 Sep; 39(9):1045-1058. PubMed ID: 34105083
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of palbociclib plus fulvestrant as second-line therapy of women with HR+/HER2- advanced breast cancer - A Chinese healthcare system perspective.
Zhu W; Zheng M; Xia P; Hong W; Ma G; Shen A
Front Oncol; 2023; 13():1068463. PubMed ID: 36998437
[TBL] [Abstract][Full Text] [Related]
11. Is Palbociclib a cost-effective strategy in the second-line treatment of metastatic breast cancer in Iran?
Darvishi A; Abdi Dezfouli R; Fazaeli A; Daroudi R; Zandieh N
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(10):1201-1210. PubMed ID: 37768209
[TBL] [Abstract][Full Text] [Related]
12. CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis.
Zeng N; Han J; Liu Z; He J; Tian K; Chen N
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444496
[TBL] [Abstract][Full Text] [Related]
13. Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.
Gupta N; Gupta D; Dixit J; Mehra N; Singh A; Krishnamurthy MN; Jyani G; Rajsekhar K; Kalaiyarasi JP; Roy PS; Malik PS; Mathew A; Malhotra P; Gupta S; Kumar L; Kataki A; Prinja S
Appl Health Econ Health Policy; 2022 Jul; 20(4):609-621. PubMed ID: 35534752
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of elacestrant versus standard endocrine therapy for second-/third-line treatment of patients with HR+/HER2- advanced or metastatic breast cancer: a US payer perspective.
Zeng W; Cao X; Lin J; Zheng B; Li N; Liu M; Cai H
Front Oncol; 2023; 13():1272586. PubMed ID: 38169749
[TBL] [Abstract][Full Text] [Related]
15. Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2- Advanced Breast Cancer in the USA?
Wu W; Lin H; Cai J; Sun H; Liu J; Hu C; Wei X
Clin Drug Investig; 2023 Dec; 43(12):939-948. PubMed ID: 37975961
[TBL] [Abstract][Full Text] [Related]
16. Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis.
Huang X; Weng X; Lin S; Liu Y; Luo S; Wang H; Ming WK; Huang P
BMJ Open; 2020 Aug; 10(8):e036107. PubMed ID: 32868353
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of ribociclib plus letrozole
Buehler AM; Castilho G; Dionne PA; Stefani S
Ther Adv Med Oncol; 2021; 13():17588359211000593. PubMed ID: 33948121
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.
Lertjanyakun V; Chaiyakunapruk N; Kunisawa S; Imanaka Y
Pharmacoeconomics; 2018 Sep; 36(9):1113-1124. PubMed ID: 29707743
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2- advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2.
Cameron D; Kumar Sharma V; Biswas C; Clarke C; Chandiwana D; Pathak P
J Med Econ; 2023; 26(1):357-365. PubMed ID: 36797664
[TBL] [Abstract][Full Text] [Related]
20. Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model.
Rui M; Shi F; Shang Y; Meng R; Li H
Adv Ther; 2020 Sep; 37(9):3761-3774. PubMed ID: 32647912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]